Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test COVID-19 Special Report: Lessons in delivering emergency care in new settings Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst FDA authorizes first COVID-19 test for screening people without symptoms Europe's COVID-19 vaccine negotiations hit snags with 3 drugmakers: Reuters Healthcare roundup: 1 in 3 hospital pharmacies face shortage of remdesivir, survey funds Biopharma roundup: Moderna kicks off late-stage vaccine trial; E.U. supply talks with J&J, Sanofi and Pfizer stall: report Hospitals employ lessons learned in load balancing, supply chain as COVID-19 cases surge Tasso secures $17M to scale up home blood testing devices in the face of COVID-19 How has your organization weathered the COVID-19 financial storm? Health systems, we want to hear from you Icon revenue down 10% in Q2, but green shoots appearing Featured Story | By Ben Adams Moderna has been handed an extra $472 million to run its phase 3 COVID-19 vaccine test. read more |
| |
|---|
|
Top Stories By Tina Reed While the delivery of primary care largely shifted to telehealth options during the COVID-19 pandemic, Vituity Healthcare CMO Gregg Miller, M.D., sees some important shifts happening in emergency care. Here are some of the lessons he sees being learned. read more By Eric Sagonowsky On the heels of Pfizer's $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds. read more By Conor Hale The FDA has authorized LabCorp's test for broad-based screening—including for people who have not shown any symptoms and those that do not suspect they have come into contact with someone with the disease. read more By Eric Sagonowsky Numerous global drugmakers are racing ahead with COVID-19 vaccine programs, and some have begun taking orders from governments with aims to deliver hundreds of millions of doses. But negotiations between the EU and some companies have hit snags, Reuters reports. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Moderna dosed the first patients in its much-ballyhooed vaccine phase 3. Europe is hung up in vaccine supply talks with Pfizer, Sanofi and J&J—primarily over pricing, E.U. officials say. A New York City-based biopharma is testing one of its enzyme inhibitors with Tamiflu in COVID-19, and LabCorp's COVID-19 diagnostic can now be used to test patients without symptoms. read more By Robert King Hospitals have watched how systems in New York and other initial COVID-19 hot spots have fared fighting the pandemic and are now applying those strategies to combat their own surge of cases. read more By Conor Hale Tasso has received $17 million in new funding to scale up production of its self-administered blood collection devices, designed to help enable telemedicine and diagnostic testing from the home. read more By Tina Reed What has been the financial hit to your organization, how long do you expect recovery to take and what are the most effective steps your organization has taken to respond to the impacts of COVID-19? Take this survey and tell us your story. read more By Ben Adams Icon has been hit hard by the disruptions from the global pandemic, and it’s starting to show up in the balance sheet. read more |
